🔮 Better than the Oracle? Our Fair Value found this +42% bagger 5 months before Buffett bought itRead More

CME Group To Purchase NEX Group, Firms Up Trading Platform

Published 03/28/2018, 10:18 PM
Updated 07/09/2023, 06:31 AM
NXGN
-
CME
-
AEL
-
AFG
-
AB
-

CME Group Inc. (NASDAQ:CME) has agreed to acquire NEX Group plc for £10 per share in a cash-stock deal. The transaction is expected to culminate in the second half of 2019, subject to closing conditions.

The buyout could lead the acquirer to emerge as a cross-border trading powerhouse.

The Purchase Consideration

Each shareholder of NEX Group will receive 500 pence in cash and 0.0444 common shares of CME Group.

Rationale Behind the Transaction

London-based NEX Group, formerly known as ICAP (LON:NXGN) plc, focuses on electronic markets and post trade business. Adding NEX Group to CME Group’s portfolio will likely ensure recurring, subscription-based revenues for the company’s transaction-based revenue model.

While NEX Group boasts premier OTC (over the counter) post-trade products and services, CME Group aces in derivatives clearing services. The acquisition is a perfect strategic fit for the company.

CME Group will leverage NEX Group’s leading electronic FX and fixed income cash execution platforms to improve trading technology and streamline access. The buyout expands the acquirer's forex business besides widening geographies. CME Group can have trading opportunities across spot and futures FX products as well as cash, repo and futures products in U.S. Treasuries.

Both companies can leverage strengths to serve clients better. CME Group chairman and CEO Terry Duffy stated that "At a time when market participants are seeking ways to lower trading costs and manage risk more effectively, this acquisition will allow us to create significant value and efficiencies for our clients globally".

CME Group estimates $200 million in run-rate cost synergies annually by the end of 2021 from this buyout.

Post acquisition, NEX Group CEO Michael Spencer will join the CME Group board of directors.

Growth Initiatives

CME Group continuously focuses on strategic initiatives that will accelerate its growth.

The company shuttered its London-based derivatives exchange and clearing house, CME Europe and CME Clearing Europe, citing customers’ preference to trade more via CME Group’s U.S. platform. Terminating operations might lead to annual savings ranging between $10 million and $12 million, which in turn will likely impact the current year in a huge way. The same move is also expected to free up over $150 million in capital.

CME Group is concentrating more on over-the-counter clearing services on interest rate swaps and foreign exchange and therefore has plans to exit the credit default swap clearing business by mid-2018.

Shares of CME Group have gained 9.2%, outperforming the industry’s 4.6% increase. Efforts to expand and cross-sell through tactical alliances, acquisitions, new product proposals as well as a strong global footprint should further drive growth for the stock in the near term.

CME Group carries a Zacks Rank #3 (Hold).

Stocks to Consider

Some better-ranked stocks from the finance sector are AllianceBernstein Holding L.P. (NYSE:AB) , American Equity Investment Life Holding Company (NYSE:AEL) and American Financial Group, Inc. (NYSE:AFG) , each sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

AllianceBernstein, an investment manager, provides research services to its clients. The company delivered an average four-quarter positive earnings surprise of 8.54%.

American Equity Investment provides life insurance products and services in the United States. The company pulled off an average four-quarter positive surprise of 27.23%.

American Financial provides property and casualty insurance products in the United States. The company came up with an average four-quarter beat of 26.31%.

Investor Alert: Breakthroughs Pending

A medical advance is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating substantial revenue, and even more wondrous products are in the pipeline.

Cures for a variety of deadly diseases are in sight, and so are big potential profits for early investors. Zacks names 5 stocks to buy now.

Click here to see them >>



AllianceBernstein Holding L.P. (AB): Free Stock Analysis Report

American Equity Investment Life Holding Company (AEL): Free Stock Analysis Report

American Financial Group, Inc. (AFG): Free Stock Analysis Report

CME Group Inc. (CME): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.